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Abstract: In academic centers, PET/MR has taken the road to clinical nuclear medicine in the past 6 years
since the last review on its applications in head and neck cancer patients in this journal. Meanwhile, older
sequential PET + MR machines have largely vanished from clinical sites, being replaced by integrated
simultaneous PET/MR scanners. Evidence from several studies suggests that PET/MR overall performs
equally well as PET/CT in the staging and restaging of head and neck cancer and in radiation therapy
planning. PET/MR appears to offer advantages in the characterization and prognostication of head and
neck malignancies through multiparametric imaging, which demands an exact preparation and validation
of imaging modalities, however. The majority of available clinical PET/MR studies today covers FDG
imaging of squamous cell carcinoma arising from a broad spectrum of locations in the upper aerodigestive
tract. In the future, specific PET/MR studies are desired that address specific histopathological tumor
entities, nonepithelial malignancies, such as major salivary gland tumors, squamous cell carcinomas arising
in specific locations, and malignancies imaged with non-FDG radiotracers. With the advent of digital
PET/CT scanners, PET/MR is expected to partake in future technical developments, such as novel
iterative reconstruction techniques and deviceless motion correction for respiration and gross movement
in the head and neck region. Owing to the still comparably high costs of PET/MR scanners and facility
requirements on the one hand, and the concentration of multidisciplinary head and neck cancer treatment
mainly at academic centers on the other hand, a more widespread use of this imaging modality outside
major hospitals is currently limited.
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PET/MR in Head and Neck Cancer  An
Update
Martin W. Huellner, MD
In academic centers, PET/MR has taken the road to clinical nuclear medicine in the past
6 years since the last review on its applications in head and neck cancer patients in this
journal. Meanwhile, older sequential PET +MR machines have largely vanished from clini-
cal sites, being replaced by integrated simultaneous PET/MR scanners.
Evidence from several studies suggests that PET/MR overall performs equally well as PET/
CT in the staging and restaging of head and neck cancer and in radiation therapy planning.
PET/MR appears to offer advantages in the characterization and prognostication of head
and neck malignancies through multiparametric imaging, which demands an exact prepara-
tion and validation of imaging modalities, however. The majority of available clinical
PET/MR studies today covers FDG imaging of squamous cell carcinoma arising from a
broad spectrum of locations in the upper aerodigestive tract. In the future, specific PET/MR
studies are desired that address specific histopathological tumor entities, nonepithelial
malignancies, such as major salivary gland tumors, squamous cell carcinomas arising in
specific locations, and malignancies imaged with non-FDG radiotracers.
With the advent of digital PET/CT scanners, PET/MR is expected to partake in future techni-
cal developments, such as novel iterative reconstruction techniques and deviceless motion
correction for respiration and gross movement in the head and neck region. Owing to the
still comparably high costs of PET/MR scanners and facility requirements on the one hand,
and the concentration of multidisciplinary head and neck cancer treatment mainly at aca-
demic centers on the other hand, a more widespread use of this imaging modality outside
major hospitals is currently limited.
Semin Nucl Med 51:26-38 © 2020 The Author. Published by Elsevier Inc. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
PET/MR Protocols
I n order to ensure acceptance of a positron emissiontomography/magnetic resonance (PET/MR) examination
both by patients and by referring physicians, its acquisition
time should roughly not exceed the acquisition time of a full
head and neck MR protocol. Such a fully diagnostic MR pro-
tocol is usually in the range of 30-40 minutes. Furthermore,
the PET/MR acquisition time should fit within an examina-
tion slot allotted for positron emission tomography / com-
puted tomography (PET/CT).1-3 A diagnostic PET/MR scan
in head and neck cancer patients consists of a regionalized
MR scan covering the head and neck, and a whole-body
PET/MR scan covering the area from the vertex of the skull
to the mid-thighs.4
The head and neck MR scan should be acquired preferen-
tially during the last minutes of the uptake phase in order to
meet the patient’s in-house time with a PET/CT examina-
tion. Whenever possible, the regionalized MR scan should
be gadolinium contrast-enhanced, with the ulterior motive
of providing highest diagnostic accuracy and saving the
patient an additional separate MR examination. Examination
time may be saved instead by refraining from diffusion-
weighted pulse sequences and perfusion-weighted pulse
sequences, whose diagnostic yield and clinical impact
appear to be limited in the presence of PET data, although
controversy exists on this matter.3,5-7 Time may also be
saved by limiting the usually fat-suppressed T2-weighted
MR pulse sequences to only one single plane, typically axial,
and the T1-weighted contrast-enhanced fat-suppressed MR
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pulse sequences to the axial plane and another plane (coro-
nal or sagittal, depending mainly on the location of the pri-
mary tumor). Hence, the minimum requirements consist of
the following MR pulse sequences: T1-weighted non-
enhanced (axial), T2-weighted fat-suppressed (axial), T1-
weighted contrast-enhanced fat-suppressed (axial + coronal/
sagittal). Specific protocols may vary depending on the
exact clinical question, the location and extent of the pri-
mary tumor and regional metastases (eg, skull base tumors,
sinonasal tumors, possible vessel infiltration).2,3,8
The whole-body PET/MR scan usually consists of several
bins or body sections of a Dixon-type T1-weighted MR pulse
sequence, such as Liver Acquisition with Volume Accelera-
tion (LAVA)-flex, yielding different tissue contrasts, acquired
in axial plane, and a T2-weighted MR pulse sequence with or
without fat suppression, acquired in a different plane, typi-
cally coronal. Each two different MR pulse sequences per
body section are acquired simultaneously with the PET scan
and their acquisition time therefore not exceed the PET lis-
tening time per body section. Since the lung represents the
most common site of distant metastases encountered in head
and neck cancer patients, it should be addressed by a dedi-
cated MR pulse sequence for lung tissue imaging. Such may
be a motion-corrected, respiration-triggered T2-weighted
MR pulse sequence using oblique k-space trajectories or peri-
odically rotated overlapping parallel sampling (eg, PROPEL-
LER, BLADE, MultiVane etc.), or MR sequences with ultra-
short or zero time to echo.9-13 If the first type of pulse
sequence is obtained, the acquisition frame may be expanded
slightly in order to cover the upper abdomen as well. If gado-
linium contrast medium is used for the dedicated head and
neck MR scan, a second identical axial Dixon-type T1-
weighted MR pulse may be acquired after contrast adminis-
tration, covering the whole-body (Fig. 1).
An overview of results of recent major studies on PET/MR
in head and neck cancer is provided in Table 1. In this table,
if not specified otherwise, the term “head and neck cancer”
alludes to various malignant neoplasms, not limited to squa-
mous cell etiology. If no specific radiotracer is mentioned,
then FDG is implied.
T Staging
In the local staging of primary tumor extent and infiltration
of adjacent structures, the vast majority of comparative stud-
ies reports a draw between PET/MR and PET/CT.14-26 How-
ever, the median number of subjects (n = 35) in these studies
is comparably low, ranging from 14 in the study by Partovi
et al to 150 in the study by Kuhn et al.18,24 The latter authors
compared contrast-enhanced PET/CT, T2-weighted PET/MR
and contrast-enhanced T1-weighted PET/MR of the head
and neck. They report slight advantages of both PET/MR
techniques over PET/CT for local tumor staging, and particu-
lar advantages of contrast-enhanced T1-weighted PET/MR
with regard to infiltration of neighboring structures by
tumors and perineural tumor spread.24 Moreover, the assess-
ment of tumors is differently affected by imaging artifacts,
depending on their location: Tumors arising in the oral cavity
and oropharynx are more affected by artifacts on PET/CT
(mainly beam hardening artifacts from dental hardware),
while tumors arising in the hypopharynx and larynx are
more affected by artifacts on PET/MR (mainly motion arti-
facts from swallowing).24
In a cohort of 35 patients with nasopharyngeal carcinoma,
Cheng et al also report superiority of T2-weighted and non-
enhanced T1-weighted PET/MR over PET/CT in the local
tumor staging.25 They, however, do not provide data on con-
trast-enhanced PET/MR. Sekine et al specifically addressed
resectability-defining factors, such as vessel encasement, pre-
vertebral space invasion and bone invasion, and report
equally favorable performance of contrast-enhanced PET/CT
and PET/MR containing a fully diagnostic regional MR proto-
col.15 However, the identification of prevertebral space
Figure 1 Incidental dural metastasis identified on a whole-body PET/MR scan. While the lesion (arrow) is well seen on
the axial contrast-enhanced T1-weighted fat-suppressed MR image (A, LAVA-flex), it is not as easily appreciated on the
fused PET/MR image (B, arrow) because its uptake is within the range of normal cortex. Acquisition of this MR pulse
sequence takes only approximately 2:30 minutes for the whole body.
PET/MR in Head and Neck Cancer – An Update 27







Subjects PET/MR System Main Results
Covello et al, 201517 Prospective 44 Biograph mMR, Siemens High agreement on tumor ROI and PET measures among PET/MR and PET/
CT.
Rasmussen et al, 2015100 Prospective 30 Biograph mMR, Siemens FDG uptake parameters in PET/CT and PET/MR are highly reproducible
Schaarschmidt et al,
201616
Retrospective 25 Biograph mMR, Siemens PET/MR and PET/CT are equal in tumor staging and recurrence detection
Leibfarth et al, 201695 Retrospective 15 Biograph mMR, Siemens Multiparameteric PET/MR provides substantial different functional imaging
data, which may be useful for cancer treatment adaptation
Surov et al, 201698 Prospective 11 Biograph mMR, Siemens DWI and PET parameters derived from PET/MR are correlated with different
histopathological parameters, such as proliferation index and Ki 67 level.
Cavaliere et al, 201735 Prospective 16 Biograph mMR, Siemens Laryngeal carcinoma:
 PET/MR is useful for staging and may help treatment planning.
 Significant correlations of PET parameters, DWI-derived parameters and
perfusion.
Sekine et al, 201714 Prospective 27 Trimodality PET/CT+MR, GE PET/MR and PET/CT are equal in whole-body staging of head and neck
cancer.
Leifels et al, 201796 Prospective 34 Biograph mMR, Siemens Head and neck squamous cell carcinoma metabolism, diffusivity and perfu-
sion depend on tumor grading.
Sekine et al, 201715 Prospective 58 Trimodality PET/CT+MR, GE Contrast-enhanced PET/MR and contrast-enhanced PET/CT are equal in
defining local resectability of head and neck cancer.
Rasmussen et al, 201758 Prospective 21 Biograph mMR, Siemens Radiation therapy planning:
 Gross tumor volumes derived by different PET/MR techniques
(T2w, FDG-PET, DWI) are similar (82% overlap).
 No correlation between FDG uptake and DWI.
Wang et al, 201759 Prospective 11 Biograph mMR, Siemens Radiation therapy planning: Gross tumor volumes derived by PET/MR and
CT are similar.
Chan et al, 201822 Prospective 113 Biograph mMR, Siemens Nasopharyngeal carcinoma:
 T staging: PET/MR «more accurate» than MR in 4/113 subjects (no
P value reported).
 N staging: Equal accuracy of PET/MR (99.3%), PET/CT (96.3%) and MR
(98.2%) (P = 0.87).
 M staging: Similar accuracy of PET/MR (98.9%), PET/CT (97.8%) and MR
(97.6%) (no P value reported).
Becker et al, 20186 Prospective 74 Ingenuity, Philips Recurrent head and neck cancer:
 PET/MR with DWI: High sensitivity (97.4%) and specificity (91.7%) for
recurrence detection after radiochemotherapy.
 Excellent agreement between imaging-based T-stage and pathological
T-stage (kappa 0.84).












Subjects PET/MR System Main Results
Kim et al, 201872 Prospective 72 Biograph mMR, Siemens Combined PET/MR parameters (metabolic volume corrected by cellularity
derived from ADC) may predict tumor recurrence after surgery.
Jentzen et al, 201861 Prospective 16 Biograph mMR, Siemens Thyroid carcinoma:
 Neck lesion quantification with 124I-PET/MR is comparable to 124I-PET/CT
for activitiy concentrations above 1 kBq/mL.
Kirchner et al, 201968 Retrospective 10 Biograph mMR, Siemens Adenoid cystic carcinoma:
 Higher diagnostic accuracy of PET/MR (91%) vs MR (84%), P < 0.05, for
detecting locally recurrent adenoid cystic carcinoma.
 High negative predictive value of PET/MR (93%) vs MR (73%) considered
particularly useful in clinical setting.
Samo»yk-Kogaczewska et
al, 201960
Prospective 10 Biograph mMR, Siemens Radiation therapy planning: 30%-40% SUVmax works best for gross tumor
volume delineation.
Olin et al, 201999 Retrospective 11 Biograph mMR, Siemens Multiparametric PET/MR imaging analysis of head and neck cancer requires
proper preparation of imaging modalities.
Cheng et al, 202025 Not mentioned 35 Trimodality PET/CT+MR, GE Nasopharyngeal carcinoma:
 PET/MR and PET/CT are roughly equal, with slight advantages for PET/
MR in analyzing primary tumors and lymph nodes.




Not mentioned 38 Biograph mMR, Siemens PET/MR superior to CT in T staging and N staging.
Pizzuto et al, 202032 Retrospective 50 Signa PET/MR, GE Sublingual glands (not mylohyoid muscles) yield highest FDG uptake in nor-
mal floor of the mouth.
Dang et al, 202097 Prospective 23 Signa PET/MR, GE Squamous cell carcinoma: Multiparametric PET/MR may allow prognosti-
cating tumor grading.
Klain et al, 202074 Prospective 40 Biograph mMR, Siemens Thyroid carcinoma:
 PET/MR and PET/CT are equal in following-up patients with elevated
serum thyroglobulin levels after thyroidectomy and radioiodine therapy.
Huang et al, 202026 Prospective 20 Signa PET/MR, GE Hypopharyngeal carcinoma:
 T staging: Equal accuracy of PET/MR (81.6%), PET/CT (63.6%) and MR
(72.7%).
 N staging: Equal sensitivity and specificity of PET/MR, PET/CT and MR.
Park et al, 202036 Retrospective 73 Biograph mMR, Siemens PET/MR is superior to MR and PET alone in lesion classification in head and
neck cancer.













invasion and the differentiation of local tumor recurrence
and postradiogenic osteonecrosis remains a challenging task
for cross-sectional hybrid imaging, even if intravenous con-
trast is used.27,28
Most available PET/MR studies discuss rather heteroge-
neous cohorts of squamous cell carcinoma arising in the
head and neck, and some studies include non-squamous cell
malignancies as well. Data on specific tumor subsites in the
head and neck is scarce, as well as specific data on non-squa-
mous cell tumors. Also, some PET/MR studies lack compara-
tive data on PET/CT, which still serves as a standard of
reference for oncological cross-sectional hybrid imaging.
Samo»yk-Kogaczewska et al report superiority of PET/MR
over CT imaging in the primary tumor staging of a cohort of
mainly moderately differentiated (G2) squamous cell carcino-
mas of various origins.29 In a large prospective study on
nasopharyngeal carcinoma patients, Chan et al reported PET/
MR to be “more accurate” than MR in 4 out of 113 subjects,
however, without providing a P value.22 Huang et al recently
reported in 20 patients with hypopharyngeal carcinoma that
PET/MR performs equally well as PET/CT and MR, with
insignificant advantages for PET/MR (diagnostic accuracy:
PET/MR 81.6%, PET/CT 63.6%, MR 72.7%).26 In a small
cohort of oral and oropharyngeal carcinoma patients
(n = 11), all with histopathological standard of reference,
Hayashi et al reported that separately acquired and retrospec-
tively fused PET-MR images facilitate the assessment of man-
dible and medial pterygoid infiltration, both of which
rendering such a tumor either T4 (p16-positive) or T4a
(p16-negative).30 They also report that PET-MR is easy to
understand for non-radiologists, such as head and neck sur-
geons. However, retrospectively fused PET-MR images are
known to have inferior registration accuracy compared to
simultaneously acquired PET/MR image datasets in head and
neck cancer patients.31 Cavaliere et al in their study on 16
patients with laryngeal carcinoma report that PET/MR has
“relevant clinical impact”, mainly by assisting in treatment
planning (9 of 16 subjects). Endoscopic findings were con-
firmed in 6 of 16 subjects, while the endoscopic staging of
the primary tumor was modified only in one single subject.
The local assessment of head and neck tumors may be
challenged by structures that physiologically exhibit 18F-flu-
orodeoxygluocse (FDG) uptake, such as muscles or salivary
glands, and which may be closely related and exhibit similar
density on CT. A recent study by Pizzuto et al using PET/MR
confirmed that it is in fact the sublingual glands that show
physiological high FDG uptake in the floor of the mouth,
and not the mylohyoid muscles.32-34
Figure 2 Perineural spread in PET/MR (contrast-enhanced T1-weighted fat-suppressed images). FDG-avid contrast-
enhancing tumor extension is seen along the trigeminal nerve in the lateral wall of the cavernous sinus and in Meckel’s
cave (arrows on A and B), all the way to the thickened cisternal segment of the nerve and the root entry zone in the
pons (arrowhead on A and B).
Figure 3 Perineural spread in PET/MR (same subject as in Fig. 2).
FDG-avid tumor extension is seen within and below the foramen
ovale along the mandibular nerve (arrow), which is the largest of
the three major branches of the trigeminal nerve, and further behind
the condylar neck of the mandible along the auriculotemporal nerve
(arrowheads), which is the posterior and larger division of the man-
dibular nerve.
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Perineural tumor extension refers to tumor growth along
nerves and accompanying structures, in the head and neck
mainly occurring along larger cranial nerves and their
branches, sometimes unto the brain stem (Fig. 2). While the
majority of adenoid cystic carcinomas exhibit such perineural
spread, owing to their overall greater incidence, it is mainly
seen with run-of-the-mill squamous cell carcinomas (Fig. 3).
The presence of perineural spread implies a bad prognosis
for patients, and may change or preclude a surgical approach
and impact on the radiation therapy volume. Nevertheless, it
is often overlooked, even in clinically symptomatic patients.
Its detection therefore warrants scrutinizing of images. PET/
MR generally is believed to surpass both MR and PET/CT in
the assessment of perineural spread. However, so far, only a
few studies reported on this topic. Kuhn et al state that peri-
neural spread in their cohort of 150 patients with mainly T2
to T4 tumors was detected overall in 7% of subjects with
PET, in 2% with MR, and in 1% with CT. They, however, do
not provide a direct comparison of PET/MR and PET/CT.24
Such was done in a study by Sekine et al, who reported peri-
neural spread in 22% of locally advanced squamous cell car-
cinomas.15 Here, PET/MR and PET/CT reach equal high
accuracy (100% vs 98%, respectively).
NStaging
As with T staging, the majority of PET/MR studies covers
mainly unselected cohorts of head and neck cancers. An
overall equal performance in comparison with PET/CT is
reported.14,16,18,21,23,24 In nasopharyngeal carcinoma, Chan
et al report an equal diagnostic accuracy of PET/MR (99.3%),
PET/CT (96.3%), and MR (98.2%) (P = 0.87).22 In the same
tumor entity, Cheng et al report a slight advantage of T2-
weighted PET/MR imaging over T1-weighted PET/MR imag-
ing in nodal staging25 (Fig. 4). Also in the nodal staging of
hypopharyngeal carcinoma, a tumor entity that frequently
exhibits regional lymph node metastases, evidence exists that
PET/MR reaches equal sensitivity and specificity as PET/CT
and MR.26 In their study on laryngeal carcinomas, Cavaliere
et al do not comment on the N staging, probably owing to
the small cohort of only 3 nodal positive subjects out of a
total of 16.35 The larynx, particularly the glottic area with the
true vocal cords, is known for its paucity of lymphatics. Not
surprisingly, the studies by Park et al and Samo»yk-Kogac-
zewska et al report superior performance of PET/MR com-
pared to MR alone and CT alone in cohorts of squamous cell
carcinomas of various origins.29,36 In their large general head
and neck cancer cohort, Kuhn et al claimed that PET/MR
without contrast, which in their study performed equally
well as contrast-enhanced PET/CT, might hence easily
replace PET/CT in patients who cannot receive contrast
medium.24
MStaging and Second Primary
Tumors
Data is somewhat scarce concerning the M staging and the
detection of second primary tumors in patients with head
and neck cancer that underwent PET/MR. This finding might
be due to the overall comparably low median number of
study subjects on the one hand, and due to the only approxi-
mately 5%-10% of head and neck cancer patients exhibiting
distant metastases or second primary tumors at their initial
staging on the other hand.37-39
Within one year, approximately 10% of head and neck
cancer patients develop metachronous distant metastases,
increasing to approximately 20% by 5 years.40 Approxi-
mately two thirds of distant metastases occur in the lung, fol-
lowed by the bone and liver, if cervical soft tissue metastases
are excluded.41 While the lung initially was considered prob-
lematic for PET/MR, in oncological populations it actually
turned out to work well.42-44 Dedicated MR pulse sequences
for lung imaging used in PET/MR can detect nodules of only
3 mm size on the one hand, while on the other hand nodules
Figure 4 Nasopharyngeal carcinoma. The FDG-avid tumor (arrow) arises in the left-sided fossa of Rosenm€uller, as seen
on the axial contrast-enhanced T1-weighted fat-suppressed MR image (A), T2-weighted fat-suppressed MR image (B)
and fused PET/MR image (C). No infiltration of the prevertebral space by the primary tumor is seen. However, a T2w-
hyperintense, FDG-negative lateral retropharyngeal lymph node metastasis (arrowhead) is seen adjacent to the prever-
tebral muscles, rendering the patient ineligible for surgery.
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missed on PET/MR do not grow in 97%, and FDG-negative
sub-centimeter nodules are benign in >98%.14,45-47 Novel
MR pulse sequence with zero time to echo (ZTE) are becom-
ing available in PET/MR and show promising results for the
assessment of lung parenchyma.11
A large recent meta-analysis covering more than 450,000
head and neck cancer patients showed that 5% of patients
have synchronous second primary tumors, and 13% of
patients will have metachronous primary tumors within 2
years’ time.38 The majority of second primary tumors occur
in the upper aerodigestive tract, followed by the lung.38
Hence, PET/MR might proof valuable in the detection
of distant metastases and second primary tumors. Sekine
et al had only one single patient with distant metastasis
in their cohort of patients referred for initial staging.14
Partovi et al had a total of 38 distant metastases in their
cohort of 14 patients referred mainly for restaging, and
report a similar performance of PET/MR and PET/CT in
assessing these lesions, but do not specifically comment
on staging.18 Chan et al report similar diagnostic accuracy
of PET/MR (98.9%), PET/CT (97.8%), and MR (97.6%) in
113 nasopharyngeal carcinoma patients with a total of 30
distant metastases.
Specific PET/MR data on second primaries in head and
neck cancer patients is currently lacking. There is, however,
evidence that PET/MR might surpass PET/CT in the detec-
tion of hitherto occult primaries particularly in the head and
neck region, indicating that PET/MR might also perform well
in the incidental detection of second primaries.48,49
Radiation Therapy Planning
PET-based radiation therapy planning offers several advan-
tages over conventional morphological radiation therapy
planning in head and neck cancer patients.50-52 The probably
most important advantage lies in the more holistic identifica-
tion of disease extent  not only in the head and neck region
but also with regard to distant sites.52 Using FDG as radio-
tracer, PET-based radiation therapy planning reduces the
risk of geographical miss of radiation delivery to the gross
tumor volume in head and neck cancers.52,53 The use of
other radiotracers, such as 18F-fluoromisonidazole (F-
MISO) or 18F-fluoroazomycin (FAZA) that serve as bio-
markers for hypoxia, may characterize the biological behav-
ior of tumors, identifying tissues that deserve modulated or
escalated radiation therapy approaches.52,54 Other bio-
markers important for radiation therapy planning may also
be derived from MR imaging, such as the vascularity and per-
meability of tissues using perfusion-weighted imaging (PWI)
or the cellularity using diffusion-weighted imaging
(DWI).6,52 Increasing attention has been paid in the last years
to MR-guided radiation therapy systems, which can image
and treat cancer patients simultaneously, and first technical
studies have recently been published showing the feasibility
in head and neck cancer patients.55-57 For these reasons,
PET/MR-based radiation therapy planning appears to be an
appealing option in head and neck cancer patients.6
However, data on PET/MR-based radiation therapy plan-
ning is somewhat scarce. Three prospective studies targeted
this topic, with results in radiation therapy planning available
in 10-12 patients per study, all examined with FDG.58-60
Rasmussen et al examined different PET/MR-derived tumor
delineation techniques (T2w, FDG-PET, DWI) and reported
a similar performance of methods, with 82% overlap of gross
tumor volumes.58 Wang et al state that PET/MR-derived
gross tumor volumes also match CT-derived gross tumor
volumes, achieving similar radiation doses.59 Samo»yk-
Kogaczewska et al focused on which volume threshold of the
maximum standardized uptake value (SUVmax) serves best
for primary tumor delineation and nodal gross tumor vol-
ume, reporting best results for 30% SUVmax and 30-40%
SUVmax, respectively.
60
PET/MR-based radiation therapy planning of the head and
neck region in clinical routine requires positioning devices,
such as masks and a flat tabletop for the PET/MR gantry,
which impedes with the rather narrow gantry gauge of PET/
MR scanners. The latter represents still an unsolved issue,
limiting the clinical usage of PET/MR for radiation therapy
planning of head and neck cancer.
For radioiodine therapy planning, Jentzen et al showed
that neck lesion quantification with 124I-PET/MR is compa-
rable to 124I-PET/CT for activity concentrations above
1 kBq/mL.61 Hence, PET/MR may be used for pre-therapy





The detection of tumor persistence or recurrence within
tissues altered by surgery and/or radiotherapy is a chal-
lenging task, both for clinicians and for radiologists.
Owing to the high intrinsic soft tissue contrast, MR is
superior to CT for this task.62,63 PET/CT in the other
hand is believed to be superior to both CT and MR,
mainly owing to its high negative predictive value,
although familiarity with false-positive findings, such as
postradiogenic inflammation or muscle tonicity, is
required.32,64-66 PET/MR, combining the aforementioned
advantages of PET and MR, hence may represent an opti-
mal approach to tackle this issue.67
Queiroz et al in their study on 87 patients found that PET/
MR and PET/CT overall perform equally well in local recur-
rence detection, but explicitly mention that PET/MR specifies
focal FDG uptake better than PET/CT, thereby decreasing
false-positive results.20 Both Sekine et al and Schaarschmidt
et al also report similar performance of both modalities in the
restaging of head and neck cancer patients.14,16 Becker et al
in 74 patient with recurrent head and neck cancer report
high sensitivity (97%) and specificity (92%) for recurrence
detection after radiochemotherapy using PET/MR including
DWI, and an excellent agreement between the T stage
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derived by PET/MR imaging and the one derived by pathol-
ogy (kappa 0.84).6
In a small but selected cohort of patients (n = 10, with a
total of 32 examinations) with locally recurrent adenoid cys-
tic carcinoma, Kirchner et al reported higher diagnostic accu-
racy of PET/MR compared to MR (91% vs 84%,
respectively).68 They claimed that particularly the high nega-
tive predictive value of PET/MR compared to MR (90% vs
73%, respectively) may be beneficial in clinical routine. This
finding is not surprising, since adenoid cystic carcinoma usu-
ally exhibits comparably low but visible FDG uptake on the
one hand and frequently comes with small regional lymph
node metastases on the other hand.69-71 Hence, PET/MR
may be an optimal approach in this setting. The authors,
however, did not address extracervical recurrence, and ade-
noid cystic carcinoma is notorious for developing slowly
growing lung metastases within 2-5 years’ time. Hence, a
side-by-side comparison with PET/CT would be desirable to
properly assess the value of PET/MR for this type of tumor.
In a prospective study analyzing 72 patients before treat-
ment, Kim et al identified several PET/MR-derived bio-
markers as predictors of recurrence after surgery, among
them the metabolic tumor volume, the ratio of metabolic
tumor volume and mean apparent diffusion coefficient
(ADCmean), and the ratio of total lesion glycolysis and
ADCmean.
72 Another recent study used retrospective PET-MR
fusion and found combined FDG-PET/MR parameters
(volumes derived from DWI and FDG-PET) to predict
clinical outcome in rhabdomyosarcoma patients.73 Hence,
combined PET/MR parameters may have prognostic capabil-
ity in head and neck cancer patients.
Thyroid cancer, orphan tumors,
and non-FDG radiotracers
FDG-PET/CT represents the most accurate imaging modality
in the staging and restaging of patients with differentiated
thyroid carcinoma of an aggressive histology, with radioio-
dine-negative malignant lesions, or in patients with increased
thyroglobulin serum concentration in the absence of patho-
logic imaging findings.74 A recent study by Klain et al in 40
patients proved equal performance of PET/MR and PET/CT
in following-up 40 subjects with differentiated thyroid cancer
and elevated thyroglobulin levels.74 Jentzen et al covered the
potential of pre-therapeutic dosimetry painting in patients
with differentiated thyroid carcinoma using 124I-PET/MR
(for details, please see above).61
Specific PET/MR studies on major salivary gland tumors
are currently lacking. It is expected that PET/MR might be
useful for the work-up of such lesions, owing to the large
variety of tumor entities arising in this location and their het-
erogeneous MR signal characteristics and uptake characteris-
tics (Fig. 5).
Pourmehdi Lahiji et al reported that the overlap of hyper-
metabolism plus restricted diffusion predict unfavorable out-
come in pediatric and adolescent patients with
rhabdomyosarcoma of the neck.73 These authors, however,
used separately acquired PET and MR image datasets that
were retrospectively fused by software. To date, no data on
PET/MR using FDG, DOTA-peptides or 18F-dihydroxyphe-
nylalanine in paragangliomas of the head and neck exist.
However, a single case of a retroperitoneal pheochromocy-
toma imaged with FDG-PET/MR was reported in a study on
succinate dehydrogenase mutation-related pediatric pheo-
chromocytomas and paragangliomas.75 The generally lower
radiation exposure with PET/MR compared to PET/CT is
another indisputable advantage, particularly in the pediatric
and adolescent population.
A favorable performance of 18F-choline PET/MR has been
reported in patients with primary hyperparathyroidism and
hitherto occult parathyroid adenomas or hyperplasia.76-78
No data currently exists on 18F-choline PET/MR in parathy-
roid malignancies (Fig. 6).
Technical Issues
Motion Correction in PET/MR in Head and
Neck Cancer Patients
In head and neck cancers patients, motion affects image qual-
ity most often in two ways: First, repetitive, predictable and
unidimensional movement of the chest and upper abdomen
due to respiration, and second, non-repetitive, unpredictable
and multidimensional bulk movement in the head and neck.
Both types of motion impact on PET and MR data.
Since the lung represents an important distant site in head
and neck cancer patients with regard to metastases and
Figure 5 Acinic cell carcinoma of the parotid gland. The well-defined tumor (arrow) is T2w-hyperintense (A), enhances
only little contrast medium if any (B) and is FDG-negative (C).
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second primary tumors, a proper consideration of motion is
desired here. Since the acquisition of images covering the
whole chest (approximately 6 minutes) exceeds patients’
breathhold capability, all clinical MR pulse sequences for
lung imaging (eg, T2-weighted propeller, ZTE) use gating
devices that recognize the respiratory cycle and allow image
acquisition during the quiescent phase.9,10,42,45 Such devices
are typically external ones placed on the patient, such as bel-
lows, but image-based tracking has been used as well.18,79,80
External gating devices have also been used for motion cor-
rection of PET, either bellows or reflecting markers and infra-
red cameras. Beyond being time consuming and somewhat
uncomfortable for patients, this technique has several draw-
backs. Most importantly, motion can only be corrected for in
one single bed position, which must be prescribed before the
scan. Also, technical failure may spoil the whole acquisition.
In recent years, novel deviceless gating techniques were
developed that rely solely on PET data.81,82 These techniques
outperform external gating methods.81 In brief, PET coinci-
dence data is broken down into dynamic sinograms. A prin-
cipal component analyses then decomposes these sinograms
into a set of components with the maximum variation in data
over time. Finally, a Fourier transformation of these compo-
nents identifies respiratory motion, generating waveforms
and triggers. If significant motion is detected, it is automati-
cally corrected.83 This software-based method today is only
available with PET/CT scanners, but is expected to be imple-
mented in PET/MR scanners as well.
Things are more complicated with bulk motion of the
head and neck, which is typically nonrepetitive, unpredict-
able and may occur in more than one direction. Software-
based solutions for PET are expected to solve this problem in
the future.84,85 Unlike PET, MR acquisition is typically
repeated if it is spoiled by bulk motion, but correction meth-
ods exist as well.84 The combination of PET and MR bulk
motion correction techniques might amend the known swal-
lowing-related shortcomings of PET/MR compared to PET/
CT that are encountered in the larynx and hypopharynx.24
Dental Artifacts
Artifacts elicited by dentures and other metallic dental work
are known to impact on PET/MR image quality, both by dis-
torting the MR-based attenuation correction of PET emission
data, and by spoiling MR image quality. Ladefoged et al
showed in 148 PET/MR patients that dental hardware leads
to severe MR signal voids, and that the resulting PET/MR arti-
facts exceed the volume of dental hardware.86 This causes
severe bias in PET data in and near to the signal voids, affect-
ing the conspicuity of lesions in the jawbone.86 Gunzinger et
al in a study with 25 subjects have shown that MR pulse
sequences with multiacquisition variable-resonance image
combination might be useful for the reduction of artifacts eli-
cited by dental implants in PET/MR, potentially improving
the diagnostic accuracy in patients with oral and oropharyn-
geal carcinoma.87
MR-based Attenuation Correction in the
Head and Neck
In the same study, Gunzinger et al have also shown that
relative errors in SUV calculation through MR-based atten-
uation correction are negligible for simulated artifacts of
0.5 cm size, but become substantial (relative error -33%) if
the artifact size is increased to 5.2 cm.87 Ladefoged et al
report an MR-based volume of susceptibility-induced sig-
nal voids on the MR-AC attenuation maps to range
between 1.6 and 520.8 mL.86 They also report significant
underestimation of SUV that is correlated with the volume
of the susceptibility artifact on the MR attenuation map,
decreasing with the distance to the signal void.86 Both of
these studies used Dixon-type MR pulse sequences for
MR-based attenuation correction. Wiesinger et al used
ZTE-based pseudo-CT image conversion in the whole
head for this purpose.88 They report this method to be
accurate, robust and fast.88
Figure 6 Parathyroid carcinoma metastasis in a patient with relapsing parathyroid hormone increase five years after
parathyroidectomy. A well-defined roundish T2w-hyperintense (A) lesion (arrow) is seen in the right-sided skull base,
exhibiting intense 18F-choline uptake on the coronal maximum intensity projection (B) and on the retrospectively
fused axial nonenhanced T1-weighted nonenhanced PET/MR image (C). The lesion was resected and confirmed by his-
topathology.
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PET Image Reconstruction Techniques
A novel PET image reconstruction technique relies on a
Bayesian penalized likelihood reconstruction algorithm
(block sequential regularized expectation maximization
[BSREM]).89,90 It yields reportedly higher signal-to-noise
ratio and higher SUV compared to conventional ordered sub-
set expectation maximization in mediastinal lymph node
assessment, but does not improve the accuracy of N stag-
ing.91 Another study showed that artificial intelligence using
deep learning yields better results in lung nodule assessment
with BSREM compared to ordered subset expectation maxi-
mization.92 While BSREM is used on many digital PET/CT
scanners, it is also increasingly available on PET/MR scan-
ners.93 To date, no results have been published concerning
the use of BSREM in PET/MR in head and neck cancer
patients.
Functional MR Techniques and
Multiparametric PET/MR
In a clinical setting, Queiroz et al have shown that the addi-
tion of DWI does not provide additional value for the staging
of 70 head and neck cancer patients with PET/MR, while
Becker et al pointed out that DWI might be particularly use-
ful to detect local tumor recurrence.5,6
Most research questions about multiparametric PET/MR
using different functional MR techniques in conjunction
with PET revolve around the additive value of such techni-
ques and their use as surrogate markers  alone or in
combination  for different endpoints, such as biological
characteristics and behavior of tumor, its responsiveness
to therapy, as well as the disease-specific survival of
patients. Hitherto published PET/MR studies in head and
neck cancer cover DWI, perfusion-weighted imaging
and intravoxel incoherent motion. These studies report
different and partly contradicting results.
Varoquaux et al and Leibfarth et al found no association of
PET parameters and DWI-derived parameters in primary
tumors; both techniques might therefore be complemen-
tary.94,95 Leifels et al reported different correlations of PET
parameters with DWI parameters and PWI parameters in 34
patients with head and neck cancer, which are related to
tumor grading.96 Dang et al reported a correlation of PET
parameters with PWI parameters, but not with DWI parame-
ters in 23 patients, stating multiparametric PET/MR might
predict tumor grading.97 Surov et al in a study with 11 sub-
jects stated that primary tumor PET parameters and DWI
parameters from PET/MR are correlated with different histo-
pathological parameters, such as the proliferation index and
the Ki 67 level.98 Kim et al reported that a combination of
PET parameters and ADC may predict treatment failure (see
above).72
Caution is warranted when interpreting the results of these
studies. Beyond the rather small median number of subjects
which might limit the significance of results, comparability
of data might also be affected by the lack of inter-scanner
harmonization, different acquisition and reconstruction
techniques, and different preparation methods or the omis-
sion of such. Olin et al showed that incorporating point
spread function modelling into PET image reconstruction
affects tumor quantification (10%-20% increase in SUV).99
DWI geometric distortion can be reduced by correction
methods. Both parameters sets are influenced differently:
While the PET reconstruction technique (point spread func-
tion) has little influence on spatial correlation with DWI, dis-
tortion correction of DWI significantly affects the spatial
correlation with PET.99 Hence, in order to properly conduct,
analyze and interpret multiparametric PET/MR studies of
head and neck cancer, an appropriate preparation of the
imaging modalities is essential.99
Summary
PET/MR is a valid and clinically accepted imaging tool in the
head and neck. Overall, it provides at least equal diagnostic
accuracy as PET/CT, offering advantages over PET/CT in spe-
cific clinical situations, besides the generally lower radiation
burden. In the future, specific PET/MR studies are desired
addressing specific histopathological tumor entities and spe-
cific anatomical subsites in the head and neck, as well as
malignancies imaged with non-FDG radiotracers.
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